多西他赛与奥沙利铂联合氟尿嘧啶类药物治疗晚期胃癌的临床效果对比研究  

Comparative study on the clinical effect of docetaxel and oxaliplatin combined with fluoropyrimidines in the treatment of advanced gastric cancer

作　　者：周秀芬 刘国庆 ZHOU Xiu-fen;LIU Guo-qing(Department of Internal Medicinet Liaocheng Infectious Disease Hospital,Liaocheng 252000,China)

机构地区：[1]聊城市传染病医院内科,252000

出　　处：《中国实用医药》2020年第25期10-12,共3页China Practical Medicine

摘　　要：目的对比分析多西他赛与奥沙利铂联合氟尿嘧啶类药物治疗晚期胃癌患者的临床效果。方法 125例晚期胃癌患者,按照随机数字表法分为实验组(63例)和对照组(62例)。实验组应用奥沙利铂联合氟尿嘧啶类药物治疗,对照组应用多西他赛联合氟尿嘧啶类药物治疗。比较两组患者的近期临床治疗效果、远期临床治疗效果、不良反应(白细胞减少、外周神经毒性)发生情况。结果实验组患者近期总有效率为52.38%,与对照组的51.61%比较,差异无统计学意义(P>0.05)。实验组中位疾病进展时间为5.25个月,中位生存时间为12.96个月;对照组中位疾病进展时间为5.26个月,中位生存时间为13.01个月,两组基本无差异。实验组患者平均疾病进展时间为(5.2±0.3)个月、平均生存时间为(12.4±1.7)个月,与对照组的(5.3±0.9)、(12.9±1.4)个月比较差异无统计学意义(P>0.05)。实验组患者的白细胞减少、外周神经毒性发生率分别为63.49%(40/63)、31.75%(20/63),低于对照组的82.26%(51/62)、64.52%(40/62),差异具有统计学意义(P<0.05)。结论奥沙利铂联合氟尿嘧啶类药物治疗晚期胃癌患者的临床治疗效果与多西他赛联合氟尿嘧啶类药物治疗效果相似,但是,奥沙利铂联合氟尿嘧啶类药物治疗晚期胃癌的不良反应发生率较低。Objective To compare and analyzed the clinical effect of docetaxel and oxaliplatin combined with fluoropyrimidines in the treatment of advanced gastric cancer. Methods A total of 125 patients with advanced gastric cancer were divided into experimental group(63 cases) and control group(62 cases) by random numerical table. The experimental group was treated with oxaliplatin combined with fluoropyrimidines, and the control group was treated with docetaxel combined with fluoropyrimidines. The short-term efficacy, long-term efficacy, occurrence of adverse reactions(leukopenia and peripheral neurotoxicity) were compared between the two groups. Results The short-term total effective rate of the experimental group was 52.38%, which had no statistically significant compared with that of the control group 51.61%(P>0.05). In the experimental group, the median time to progression was 5.25 months, and the median survival time was 12.96 months;in the control group, the median time to disease progression was 5.26 months, and the median survival time was 13.01 months. There was basically no difference between the two groups. The average time to progression of the experimental group was(5.2±0.3) months, and the average survival time was(12.4±1.7) months, which had no statistically significant difference compared with those of the control group(5.3±0.9) and(12.9±1.4) months(P>0.05). The incidence of leukopenia and peripheral neurotoxicity of the experimental group was 63.49%(40/63) and 31.75%(20/63) respectively, which was lower than those of the control group 82.26%(51/62) and 64.52%(40/62), and the difference was statistically significant(P<0.05). Conclusion The clinical effect of oxaliplatin combined with fluoropyrimidines in the treatment of patients with advanced gastric cancer is similar to that of docetaxel combined with fluoropyrimidines. However, the incidence of adverse reactions of oxaliplatin combined with fluoropyrimidines in the treatment of advanced gastric cancer is low.

关 键 词：多西他赛 奥沙利铂 氟尿嘧啶类药物 晚期胃癌 临床效果 

分 类 号：R735.2[医药卫生—肿瘤]